<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=5.0">
    <title>ç§‘ç ”æ—¥æŠ¥ - 2025-12-12</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, "Noto Sans", sans-serif, "Apple Color Emoji", "Segoe UI Emoji";
            line-height: 1.8;
            color: #2c3e50;
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            padding: 15px;
            font-size: 16px;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
            background: white;
            padding: 35px;
            border-radius: 16px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }

        /* æ ‡é¢˜ä¼˜åŒ– */
        h1 {
            color: #1a202c;
            font-size: 2em;
            border-bottom: 4px solid #667eea;
            padding-bottom: 15px;
            margin-bottom: 25px;
            font-weight: 700;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }

        h2 {
            color: #2d3748;
            font-size: 1.5em;
            margin-top: 40px;
            margin-bottom: 20px;
            padding-left: 15px;
            border-left: 5px solid #667eea;
            font-weight: 600;
        }

        h3 {
            color: #4a5568;
            font-size: 1.25em;
            margin-top: 28px;
            margin-bottom: 14px;
            font-weight: 600;
        }

        /* åˆ†ç±»æµè§ˆæŠ˜å åŠŸèƒ½ */
        details {
            margin: 20px 0;
            border-radius: 8px;
            overflow: hidden;
        }

        details summary {
            cursor: pointer;
            padding: 15px 20px;
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            color: #2d3748;
            font-size: 1.25em;
            font-weight: 600;
            text-align: right;
            direction: rtl;
            border-right: 5px solid #667eea;
            transition: all 0.3s ease;
            list-style: none;
            user-select: none;
        }

        details summary * {
            direction: ltr;
        }

        details summary::-webkit-details-marker {
            display: none;
        }

        details summary::before {
            content: 'â–¶';
            display: inline-block;
            margin-left: 10px;
            transition: transform 0.3s ease;
            font-size: 0.8em;
        }

        details[open] summary::before {
            transform: rotate(90deg);
        }

        details summary:hover {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            box-shadow: 0 4px 12px rgba(102, 126, 234, 0.3);
        }

        details[open] summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            border-right-color: white;
        }

        details .details-content {
            padding: 20px;
            background: white;
            border: 1px solid #e9ecef;
            border-top: none;
        }

        h4 {
            color: #718096;
            font-size: 1.1em;
            margin-top: 22px;
            margin-bottom: 12px;
            font-weight: 600;
        }

        p {
            margin-bottom: 16px;
            line-height: 1.8;
        }

        blockquote {
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            border-left: 4px solid #667eea;
            padding: 18px 22px;
            margin: 22px 0;
            border-radius: 8px;
            color: #4a5568;
            font-size: 0.95em;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        blockquote p {
            margin-bottom: 8px;
        }

        blockquote p:last-child {
            margin-bottom: 0;
        }

        blockquote em {
            font-style: normal;
            color: #718096;
            font-size: 0.9em;
        }

        blockquote a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        blockquote a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* é¡¶éƒ¨ç½²åï¼ˆå±…å³ï¼‰ */
        .powered-by-top {
            text-align: right;
            font-size: 0.85em;
            color: #718096;
            font-style: italic;
            margin: 12px 0;
            padding-right: 5px;
        }

        .powered-by-top a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        .powered-by-top a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* AI æ€»ç»“åŒºåŸŸä¼˜åŒ– */
        .ai-summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 28px;
            border-radius: 16px;
            margin: 30px 0;
            box-shadow: 0 12px 35px rgba(102, 126, 234, 0.35);
            position: relative;
            overflow: hidden;
        }

        .ai-summary::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -50%;
            width: 200%;
            height: 200%;
            background: radial-gradient(circle, rgba(255,255,255,0.1) 0%, transparent 70%);
            pointer-events: none;
        }

        .ai-summary h2 {
            color: white;
            border-left: none;
            border-right: none;
            margin-top: 0;
            margin-bottom: 18px;
            padding-left: 15px;
            padding-right: 0;
            text-align: left;
            direction: ltr;
        }

        .ai-summary h3 {
            color: #f0f0f0;
            margin-top: 18px;
            border-right: 3px solid rgba(255,255,255,0.5);
            padding-right: 12px;
            padding-left: 0;
            text-align: right;
            direction: rtl;
        }

        .ai-summary h3 * {
            direction: ltr;
        }

        .ai-summary blockquote {
            background: rgba(255,255,255,0.15);
            border-left-color: white;
            color: white;
            backdrop-filter: blur(10px);
        }

        .ai-summary p {
            color: white;
        }

        .ai-summary strong {
            color: #fff;
            font-weight: 600;
        }

        ul, ol {
            margin-left: 28px;
            margin-bottom: 18px;
        }

        li {
            margin-bottom: 12px;
            line-height: 1.8;
        }

        /* é“¾æ¥ä¼˜åŒ– */
        a {
            color: #667eea;
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: all 0.3s ease;
            font-weight: 500;
        }

        a:hover {
            border-bottom-color: #667eea;
            color: #764ba2;
        }

        /* è¡¨æ ¼ä¼˜åŒ– */
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            box-shadow: 0 2px 12px rgba(0,0,0,0.08);
            border-radius: 10px;
            overflow: hidden;
        }

        th, td {
            border: 1px solid #e2e8f0;
            padding: 14px 18px;
            text-align: left;
        }

        th {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            font-weight: 600;
            font-size: 0.95em;
        }

        tr:nth-child(even) {
            background: #f8f9fa;
        }

        tr:hover {
            background: #e9ecef;
            transition: background 0.3s ease;
        }

        /* å…³é”®è¯ç»Ÿè®¡è¡¨æ ¼ç‰¹æ®Šæ ·å¼ï¼ˆæ›´ç´§å‡‘ï¼‰ */
        .keywords-table {
            font-size: 0.9em;
            max-width: 600px;
        }

        .keywords-table th,
        .keywords-table td {
            padding: 10px 14px;
        }

        .keywords-table th {
            font-size: 0.9em;
        }

        hr {
            border: none;
            border-top: 2px solid #e2e8f0;
            margin: 40px 0;
        }

        strong {
            color: #2d3748;
            font-weight: 600;
        }

        code {
            background: #f1f5f9;
            padding: 3px 8px;
            border-radius: 5px;
            font-family: "SF Mono", Monaco, Consolas, "Courier New", monospace;
            font-size: 0.9em;
            color: #e53e3e;
        }

        /* ç¾åŒ–æ»šåŠ¨æ¡ */
        ::-webkit-scrollbar {
            width: 8px;
            height: 8px;
        }

        ::-webkit-scrollbar-track {
            background: #f1f1f1;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb {
            background: #667eea;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb:hover {
            background: #764ba2;
        }

        /* ç§»åŠ¨ç«¯ä¼˜åŒ– */
        @media (max-width: 768px) {
            body {
                padding: 8px;
                font-size: 15px;
            }

            .container {
                padding: 22px 18px;
                border-radius: 12px;
            }

            h1 {
                font-size: 1.6em;
                padding-bottom: 12px;
                margin-bottom: 20px;
            }

            h2 {
                font-size: 1.3em;
                margin-top: 30px;
                padding-left: 12px;
            }

            h3 {
                font-size: 1.15em;
            }

            h4 {
                font-size: 1.05em;
            }

            blockquote {
                padding: 14px 16px;
                margin: 18px 0;
            }

            .ai-summary {
                padding: 20px;
                margin: 22px 0;
            }

            .ai-summary-header {
                flex-direction: column;
                align-items: flex-start;
            }

            .powered-by {
                margin-left: 0;
                margin-top: 8px;
            }

            table {
                font-size: 0.85em;
            }

            th, td {
                padding: 10px 12px;
            }

            .keywords-table {
                font-size: 0.8em;
            }

            .keywords-table th,
            .keywords-table td {
                padding: 8px 10px;
            }

            ul, ol {
                margin-left: 22px;
            }
        }

        /* è¶…å°å±å¹• */
        @media (max-width: 480px) {
            body {
                font-size: 14px;
                padding: 5px;
            }

            .container {
                padding: 18px 14px;
            }

            h1 {
                font-size: 1.4em;
            }

            h2 {
                font-size: 1.2em;
            }

            .ai-summary {
                padding: 16px;
            }

            .powered-by {
                font-size: 0.7em;
            }
        }

        /* å¹³æ»‘æ»šåŠ¨ */
        html {
            scroll-behavior: smooth;
        }

        /* æé«˜å¯ç‚¹å‡»åŒºåŸŸ */
        @media (pointer: coarse) {
            a {
                padding: 4px 0;
                display: inline-block;
            }
        }

        /* æ‰“å°ä¼˜åŒ– */
        @media print {
            body {
                background: white;
                padding: 0;
            }

            .container {
                box-shadow: none;
                max-width: 100%;
            }

            .ai-summary {
                background: #f5f5f5;
                color: black;
                box-shadow: none;
            }

            .ai-summary h2,
            .ai-summary h3,
            .ai-summary p,
            .ai-summary strong {
                color: black;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>ğŸ“… Daily Report - 2025-12-12</h1>
<blockquote>
<p>ä»Šæ—¥ç­›é€‰å‡º <strong>61</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>2</strong> ä¸ªæ¥æº</p>
</blockquote>
<div class="powered-by-top">Powered by <a href="https://kyplus.de" target="_blank" rel="noopener noreferrer">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai" target="_blank" rel="noopener noreferrer">Claude</a></div>

<hr />
<div class="ai-summary">
                <h2>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2>
                <h3>ğŸ§¬ æ•°æ®å‰æ²¿</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
é¦–æ¬¡æ­ç¤ºè°·æ°¨é…°èƒºåˆæˆé…¶ï¼ˆGSï¼‰åœ¨Î²-cateninçªå˜è‚ç™Œä¸­ç¼ºå¤±å¦‚ä½•é‡å¡‘è°·æ°¨é…°èƒºä»£è°¢ï¼Œé©±åŠ¨å…ç–«æŠ‘åˆ¶æ€§å·¨å™¬ç»†èƒé€‚åº”ï¼Œä¸ºè‚¿ç˜¤å…ç–«æ²»ç–—æä¾›æ–°é¶ç‚¹ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- è‚¿ç˜¤ä»£è°¢é‡å¡‘ä¸å…ç–«é€ƒé€¸æœºåˆ¶ï¼ˆè‚ç™Œã€è†€èƒ±ç™Œã€éå°ç»†èƒè‚ºç™Œã€ä¹³è…ºç™Œï¼‰<br />
- ç»†èƒä¿¡å·é€šè·¯è°ƒæ§ä¸ç–¾ç—…è¿›å±•ï¼ˆWntã€EGFR-TKIã€é›„æ¿€ç´ å—ä½“ã€çƒ­ä¼‘å…‹é€šè·¯ï¼‰<br />
- è‚ é“èŒç¾¤ä»£è°¢äº§ç‰©ä¸è‚ é“ç¨³æ€ç»´æŒ<br />
- ç¥ç»é€€è¡Œæ€§ç–¾ç—…ï¼ˆC9orf72çªå˜ã€Tauç—…ç†ï¼‰çš„å•ç»†èƒè½¬å½•ç»„åˆ†æ</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- ç©ºé—´è½¬å½•ç»„å­¦æŠ€æœ¯åœ¨å¿ƒè¡€ç®¡ç–¾ç—…ï¼ˆç³–å°¿ç—…å† è„‰å¾®å¾ªç¯ã€åŠ¨è„‰ç²¥æ ·ç¡¬åŒ–è¡€æ “ï¼‰ç ”ç©¶ä¸­çš„åº”ç”¨ï¼Œæ­ç¤ºåŒºåŸŸå¼‚è´¨æ€§ã€‚<br />
- ç»“åˆå•ç»†èƒRNAæµ‹åºå’Œå…¨åŸºå› ç»„äºšç¡«é…¸æ°¢ç›æµ‹åºï¼Œæ·±å…¥è§£æç»†èƒå¼‚è´¨æ€§ã€åŸºå› ç»„ç”²åŸºåŒ–ä¸å‘è‚²ã€ç–¾ç—…çš„å…³è”ã€‚</p>
<h3>ğŸ§ª åšå®¢æ›´æ–°</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
æ–°å‹MUTE-SeqæŠ€æœ¯æœ‰æœ›å®ç°å¯¹ä½é¢‘ç™Œç—‡çªå˜çš„è¶…çµæ•æ£€æµ‹ï¼›è‚¥èƒ–è¢«è¯å®èƒ½æ˜¾è‘—åŠ é€Ÿé˜¿å°”èŒ¨æµ·é»˜ç—…çš„è¿›å±•ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- ç™Œç—‡çªå˜æ£€æµ‹ï¼šé€šè¿‡å¯Œé›†ç¨€æœ‰çªå˜ï¼Œæé«˜æ¶²ä½“æ´»æ£€çš„çµæ•åº¦ã€‚<br />
- é˜¿å°”èŒ¨æµ·é»˜ç—…ç ”ç©¶ï¼šæ­ç¤ºè‚¥èƒ–å¯¹ç–¾ç—…è¿›å±•çš„åŠ é€Ÿä½œç”¨ã€‚<br />
- ç™Œç—‡æ²»ç–—æŠµæŠ—æœºåˆ¶ï¼šå‘ç°ç™Œç»†èƒåˆ©ç”¨DNAé™è§£é…¶çš„ç”Ÿå­˜ç­–ç•¥ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- MUTE-Seqï¼šé€šè¿‡å»é™¤é‡ç”Ÿå‹DNAæ¥å¯Œé›†ç¨€æœ‰çªå˜ã€‚<br />
- æ—©æœŸç”Ÿç‰©æ ‡å¿—ç‰©æ£€æµ‹ï¼šåˆ©ç”¨è¡€æ¶²æ£€æµ‹å¿«é€Ÿè¯„ä¼°è‚¥èƒ–å¯¹é˜¿å°”èŒ¨æµ·é»˜ç—…çš„å½±å“ã€‚</p>
            </div><h2>ğŸ“š åˆ†ç±»æµè§ˆ</h2>
<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (58æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>GSE298611 Î²-cateninçªå˜å‹è‚ç»†èƒç™Œä¸­è°·æ°¨é…°èƒºåˆæˆé…¶çš„ç¼ºå¤±é‡å¡‘è°·æ°¨é…°èƒºä»£è°¢ï¼Œä¿ƒè¿›å…ç–«æŠ‘åˆ¶æ€§å·¨å™¬ç»†èƒçš„é€‚åº” [dataset1.Spatial.Transcriptomics]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcarcinomaã€macrophageã€metabolismã€spatialã€transcriptomics<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Evan R Dalgado ; Panari Patel ; Junyan Tao ; Yekaterina Krutsenko ; Silvia Liu ; Daniel Green ; Raghad Alzubali ; Brandon M Lehrich ; Jia-Jun Liu ; Tyler Yasaka ; Minakshi Poddar ; Sucha Singh ; Vik Meadows ; Aaron W Bell ; Aatur Singhi ; Satdarshan MongaSeries Type : OtherOrganism : Mus musculusRecent therapeutic strategies using immune checkpoint inhibitors (ICIs) to treat hepatocellular carcinoma (HCC) have shown modest success. Response to ICIs is heterogeneous, and while mutational burden may predict stable responses, some HCCs with poor prognostic markers (e.g., CTNNB1 mutations) may still respond under favorable tumor immune microenvironment (TIME) conditions. We show that Î²-catenin-mutated HCCs lacking glutamine synthetase (GS) exhibit aggressive disease due to altered glutamate/glutamine (Glu/Gln) availability, driving macrophage adaptation that promotes immunosuppression. Loss of HCC Glul (encoding GS) forces hepatic macrophages to redistribute effort from immunologic to metabolic functions. Notably, depleting macrophages in GS-deficient, Î²-catenin-mutant HCC models improves survival. Additionally, HCC GS loss results in macrophage GS overexpression that maintains mTOR signaling in tumors, which is targetable. These findings reveal a metabolic dynamic between HCCs and the TIME which suggests that metabolic profiling, including GS expression, may refine patient selection for ICI therapies and improve outcomes under current standards of care.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298611" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>GSE300260 AMPKä¾èµ–çš„è¡¨è§‚é—ä¼ ä»£è°¢è°ƒæ§ä»‹å¯¼ç´«æª€èŠªåœ¨è‚ç»†èƒç™Œä¸­çš„æŠ—ç™Œä½œç”¨ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€carcinomaã€metabolismã€epigenetic<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Cayla Boycott ; Megan Beetch ; Katarzyna Lubecka-Gajewska ; Benjamin S Ramsey ; Sandra Torregrosa-Allen ; Bennett D Elzey ; Abigail Cox ; Nadia Atallah Lanman ; Aline de Conti ; Min Li ; Mario Ferruzzi ; Igor Pogribny ; Barbara Stefanska (corresponding author)Series Type : Expression profiling by high throughput sequencingOrganism : Rattus norvegicusScope: Disrupted metabolism, often implicated in hepatocellular carcinoma (HCC), is linked to aberrant epigenetic patterns. Dietary polyphenols, including pterostilbene (PTS), have been demonstrated to remodel epigenetic landscapes and restore metabolic homeostasis by regulating the activity of AMP-activated protein kinase (AMPK), a protein recently shown to orchestrate a diverse set of networks to epigenetically mediate transcription. We therefore explored the mechanistic involvement of AMPK in the epigenetic effects of PTS in HCC. Methods and Results: We incorporated PTS into a choline-deficient amino acid defined HCC-inducing diet (CDAA) in male Fisher-344 rats and found significant attenuation in HCC development compared to CDAA alone. Transcriptomics by RNA-sequencing revealed PTS-upregulated targets, that were enriched in key metabolic processes, including the folate (Aldh1l1), methionine (Bhmt) and sarcosine (Dmdgh) cycles. PTS-mediated gene upregulation was linked to lower levels of histone H3-methylation at lysine 27 (H3K27me3) at gene promoters. Mechanistic studies in HCC HepG2 cells revealed that AMPK inhibition abolished epigenetic gene activation in response to PTS, which was accompanied by diminished binding of H3K27me3-demethylase KDM6A at promoters of PTS-target genes. Conclusion: Our findings provide evidence for new disease vulnerabilities that arise from epigenetic/metabolic changes and constitute novel opportunities for preventative and therapeutic success in HCC.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300260" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>GSE290189 SHMT2 modulates the transcriptome and metabolism profiles to promote the tumor phenotypes of bladder cancer HT-1376 cells</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancerã€metabolismã€transcriptome<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Xiaobo Guo ; Gang LiSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensBladder cancer (BLCA) is a common malignant tumor of the urinary system. The development and progression of BLCA are controlled by multiple regulatory molecules, which have not been widely investigated. In this study, we explored the functions and downstream targets of serine hydroxy methyltransferase 2 (SHMT2) by silencing its expression using small interference RNA (siSHMT2) in HT-1376 cells. Whole transcriptome and metabolism profiles were deeply analyzed to identify the molecular targets of SHMT2. We found that siSHMT2 significantly reduced the proliferation rate and altered the cell cycle stages of HT-1376 cells. Moreover, siSHMT2 can modulate the expression of hundreds of genes (DEGs), including 126 upregulated and 106 downregulated DEGs. We then found that the most significant DEGs were tightly associated with progression of cancers, including PTMA, HNRNPR, RAPH1, TRAF3IP1, CNBP, and PRR15. At the same time, the alternative splicing profile was also regulated by siSHMT2, including the skipped exon as the dominant AS types. Finally, we identified the differential metabolites (DMs), and found the metabolism profile was significantly regulated by siSHMT2. Besides the purine metabolism, we observed that valine, leucine and isoleucine biosynthesis and degradation, TCA cycle, and propanoate metabolism were among the top pathways of DMs. In summary, we highlight the important roles of SHMT2 in HT-1376 cells and identified its downstream molecular targets, which are associated with the development of BLCA and can be used as therapeutic targets of BLCA in future.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290189" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> â­ <strong>GSE298616 Î²-cateninçªå˜å‹è‚ç»†èƒç™Œä¸­è°·æ°¨é…°èƒºåˆæˆé…¶çš„ç¼ºå¤±é‡å¡‘è°·æ°¨é…°èƒºä»£è°¢ï¼Œä¿ƒè¿›å…ç–«æŠ‘åˆ¶æ€§å·¨å™¬ç»†èƒçš„é€‚åº”</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcarcinomaã€macrophageã€metabolism<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Other ; Expression profiling by high throughput sequencingOrganism : Mus musculusThis SuperSeries is composed of the SubSeries listed below.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298616" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> â­ <strong>GSE298614 Î²-cateninçªå˜è‚ç»†èƒç™Œä¸­è°·æ°¨é…°èƒºåˆæˆé…¶çš„ç¼ºå¤±é‡å¡‘è°·æ°¨é…°èƒºä»£è°¢ï¼Œä¿ƒè¿›å…ç–«æŠ‘åˆ¶æ€§å·¨å™¬ç»†èƒçš„é€‚åº” [dataset3.scRNAseq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcarcinomaã€macrophageã€metabolism<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Evan R Dalgado ; Panari Patel ; Junyan Tao ; Yekaterina Krutsenko ; Silvia Liu ; Daniel Green ; Raghad Alzubali ; Brandon M Lehrich ; Jia-Jun Liu ; Tyler Yasaka ; Minakshi Poddar ; Sucha Singh ; Vik Meadows ; Aaron W Bell ; Aatur Singhi ; Satdarshan MongaSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusRecent therapeutic strategies using immune checkpoint inhibitors (ICIs) to treat hepatocellular carcinoma (HCC) have shown modest success. Response to ICIs is heterogeneous, and while mutational burden may predict stable responses, some HCCs with poor prognostic markers (e.g., CTNNB1 mutations) may still respond under favorable tumor immune microenvironment (TIME) conditions. We show that Î²-catenin-mutated HCCs lacking glutamine synthetase (GS) exhibit aggressive disease due to altered glutamate/glutamine (Glu/Gln) availability, driving macrophage adaptation that promotes immunosuppression. Loss of HCC Glul (encoding GS) forces hepatic macrophages to redistribute effort from immunologic to metabolic functions. Notably, depleting macrophages in GS-deficient, Î²-catenin-mutant HCC models improves survival. Additionally, HCC GS loss results in macrophage GS overexpression that maintains mTOR signaling in tumors, which is targetable. These findings reveal a metabolic dynamic between HCCs and the TIME which suggests that metabolic profiling, including GS expression, may refine patient selection for ICI therapies and improve outcomes under current standards of care.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298614" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> â­ <strong>GSE298613 Î²-cateninçªå˜è‚ç»†èƒç™Œä¸­è°·æ°¨é…°èƒºåˆæˆé…¶çš„ç¼ºå¤±é‡å¡‘è°·æ°¨é…°èƒºä»£è°¢ï¼Œä¿ƒè¿›å…ç–«æŠ‘åˆ¶æ€§å·¨å™¬ç»†èƒçš„é€‚åº” [dataset2.scRNAseq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcarcinomaã€macrophageã€metabolism<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Evan R Dalgado ; Panari Patel ; Junyan Tao ; Yekaterina Krutsenko ; Silvia Liu ; Daniel Green ; Raghad Alzubali ; Brandon M Lehrich ; Jia-Jun Liu ; Tyler Yasaka ; Minakshi Poddar ; Sucha Singh ; Vik Meadows ; Aaron W Bell ; Aatur Singhi ; Satdarshan MongaSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusRecent therapeutic strategies using immune checkpoint inhibitors (ICIs) to treat hepatocellular carcinoma (HCC) have shown modest success. Response to ICIs is heterogeneous, and while mutational burden may predict stable responses, some HCCs with poor prognostic markers (e.g., CTNNB1 mutations) may still respond under favorable tumor immune microenvironment (TIME) conditions. We show that Î²-catenin-mutated HCCs lacking glutamine synthetase (GS) exhibit aggressive disease due to altered glutamate/glutamine (Glu/Gln) availability, driving macrophage adaptation that promotes immunosuppression. Loss of HCC Glul (encoding GS) forces hepatic macrophages to redistribute effort from immunologic to metabolic functions. Notably, depleting macrophages in GS-deficient, Î²-catenin-mutant HCC models improves survival. Additionally, HCC GS loss results in macrophage GS overexpression that maintains mTOR signaling in tumors, which is targetable. These findings reveal a metabolic dynamic between HCCs and the TIME which suggests that metabolic profiling, including GS expression, may refine patient selection for ICI therapies and improve outcomes under current standards of care.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298613" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> â­ <strong>GSE298111 GLMPé€šè¿‡æ¿€æ´»è‡ªå™¬å’ŒRhoAé€šè·¯ä¿ƒè¿›éå°ç»†èƒè‚ºç™Œçš„EGFR-TKIè€è¯æ€§</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€resistanceã€pathway<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Xiao Liang ; Jiali Xu ; Erbao Zhang ; Renhua GuoSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensHere, we report that the EGFR-TKI resistance mechanism is mediated by lysosome-related regulation. We established an osimertinib-resistant cell line, designated PC9OR, derived from the parental PC9 cells. The overexpression of glycosylated lysosomal membrane protein (GLMP) in PC9OR promotes resistance to Osimertinib. Mechanistically, GLMP could regulate the ubiquitination of RhoA and promote resistance by activating the epithelial-mesenchymal transition (EMT). Our findings provide a potential therapeutic strategy to overcome resistance to EGFR-TKIs.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298111" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> â­ <strong>GSE296966 é›„æ¿€ç´ å—ä½“ä¿ƒè¿› ER çªå˜ä¹³è…ºç™Œä¸­çš„çº¿ç²’ä½“æ°§åŒ–ç£·é…¸åŒ–ã€è‚‰ç¢±ä»£è°¢å’Œå¯¹æ£•æ¦ˆé…¸è„‚æ¯’æ€§çš„æŠµæŠ—ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€metabolismã€resistance<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Sessions Dane ; Spoelstra Nicole ; Caino Cecilia ; Yu Min ; Goodspeed Andrew ; Richer JenniferSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThe effect of androgen receptor (AR) in ER+ breast cancer remains controversial. We find that AR promotes tumor cell growth, oxidative phosphorylation, and fatty acid oxidation under conditions mimicking long-term aromatase inhibition. AR also promotes expression of the mitochondrial and peroxisomal acylcarnitine synthesis enzyme CRAT. AR inhibition decreases CRAT expression and CRAT knockdown is sufficient to inhibit OXPHOS. AR inhibition does not elicit a broad anti-OXPHOS transcriptomic signature, but does affect the expression of a few key metabolic enzymes. AR antagonism also induces a metabolomic signature consistent with severe OXPHOS dysfunction. This work identifies AR as a regulator of CRAT and OXPHOS in ER+ breast cancer.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296966" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> â­ <strong>GSE313152 ä¹³è…ºç™Œæ‚£è€…è‚ºè½¬ç§»ç¶å’Œæ­£å¸¸è‚ºç»„ç»‡çš„å•ç»†èƒ RNA æµ‹åºã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€sequencingã€single-cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : C E Caldon ; Leila EshraghiSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThe estrogen receptor (ER) drives growth in most breast cancers. Endocrine therapy reduces recurrence, however around 30% of cancers relapse. Many recurrences occur years later, with slowly proliferating, hard-to-treat disease. To study this, we generated slow-growing resistant cells that form small primary tumours but readily metastasize. Single-cell RNA sequencing (scRNAseq) revealed that endocrine therapy reprograms these cells, notably upregulating the Rac1 signalling component P-Rex1. We found in clinical cohorts that P-Rex1 is high in ER+ breast cancer, including in late recurrent disease.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313152" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> â­ <strong>GSE255130 è‚ é“èŒç¾¤ä»£è°¢äº§ç‰©å²å“š-3-ä¹™é…¸é€šè¿‡è½¬å½•å› å­AHRç»´æŒè‚ é“ä¸Šçš®ç¨³æ€</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šgutã€regex:gut(-?microbiome)?ã€regex:intestin(e|al)<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributor : Mengfan LiSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Mus musculusThe incidence and prevalence of inflammatory bowel disease (IBD) is gradually increasing. A high-fat diet (HFD) is known to disrupt intestinal homeostasis and aggravate IBD, yet the underlying mechanisms remain largely undefined. Here, a positive correlation between dietary fat intake and disease severity in both IBD patients and HFD-fed mice is observed. HFD induces a significant decrease in indole-3-acetic acid (IAA) and lead to intestinal barrier damage. Furthermore, IAA supplementation enhances the intestinal mucin sulfation and effectively alleviates colitis. Mechanistically, IAA upregulates key molecules involved in mucin sulfation, including Papss2 and Slc35b3, the synthesis enzyme and the transferase of 3'-phosphoadenosine-5'-phosphosulfate (PAPS), via the Aryl Hydrocarbon Receptor (AHR). More importantly, AHR can directly bind to the transcription start site of Papss2. Oral administration of Lactobacillus reuteri, which can produce IAA, contributes to protecting against colitis and promoting mucin sulfation, while the modified L. reuteri strain lacking the iaaM gene (LactobacillusÎ”iaaM) and the ability to produce IAA fails to exhibit such effects. Overall, IAA enhances intestinal mucin sulfation through AHR, contributing to the protection of intestinal homeostasis.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE255130" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 48 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-æ•°æ®å‰æ²¿">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (3æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨3æ¡ï¼‰</h4>
<p><strong>1.</strong> <strong>MUTE-Seqâ€”â€”ä¸€ç§æ£€æµ‹ä½é¢‘ç™Œç—‡çªå˜çš„è¶…çµæ•æ–¹æ³•</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šMUTE-Seq enriches rare cancer mutations by removing wild-type DNA, enabling highly sensitive detection that enhances liquid biopsy..<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/mute-seq-ultrasensitive-method-to-detect-low-frequency-cancer-mutations/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> <strong>è¡€æ¶²æ£€æµ‹æ˜¾ç¤ºï¼Œè‚¥èƒ–ä¼šè¿…é€ŸåŠ é€Ÿé˜¿å°”èŒ¨æµ·é»˜ç—…çš„å‘å±•è¿›ç¨‹ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šAlzheimer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šObesity accelerates the rise of Alzheimerâ€™s-related blood biomarkers far more rapidly than previously recognized. Long-term imaging and plasma data show that obese individuals experience much faster increases in proteins linked to neurodegeneration and amyloid buildup. Surprisingly, blood tests detected these changes earlier than PET scans. The results point to obesity as a major, modifiable contributor to Alzheimerâ€™s progression.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2025/12/251210092019.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> <strong>ç§‘å­¦å®¶æ­ç¤ºç™Œç—‡å¾—ä»¥åå¼¹çš„éšè—ç”Ÿå­˜ç§˜è¯€</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šScientists discovered that certain cancer cells use a low-level activation of a DNA-dismantling enzymeâ€”normally seen in cell deathâ€”to survive treatment. Instead of dying, these â€œpersister cellsâ€ leverage this sublethal signal to regrow. Because the mechanism is non-genetic, it appears much earlier than typical resistance mutations. Targeting this enzyme could help stop tumors from returning.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2025/12/251210092022.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<h2>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2>
<table class="keywords-table">
<thead>
<tr>
<th>å…³é”®è¯</th>
<th>å‡ºç°æ¬¡æ•°</th>
</tr>
</thead>
<tbody>
<tr>
<td>cancer</td>
<td>9</td>
</tr>
<tr>
<td>immune</td>
<td>8</td>
</tr>
<tr>
<td>metabolism</td>
<td>8</td>
</tr>
<tr>
<td>sequencing</td>
<td>7</td>
</tr>
<tr>
<td>RNA-seq</td>
<td>6</td>
</tr>
<tr>
<td>carcinoma</td>
<td>6</td>
</tr>
<tr>
<td>spatial</td>
<td>6</td>
</tr>
<tr>
<td>single-cell</td>
<td>5</td>
</tr>
<tr>
<td>genome</td>
<td>5</td>
</tr>
<tr>
<td>macrophage</td>
<td>5</td>
</tr>
<tr>
<td>tumor</td>
<td>4</td>
</tr>
<tr>
<td>transcriptome</td>
<td>4</td>
</tr>
<tr>
<td>scRNA</td>
<td>3</td>
</tr>
<tr>
<td>epigenetic</td>
<td>2</td>
</tr>
<tr>
<td>resistance</td>
<td>2</td>
</tr>
<tr>
<td>pathway</td>
<td>2</td>
</tr>
<tr>
<td>transcriptomics</td>
<td>1</td>
</tr>
<tr>
<td>T cell</td>
<td>1</td>
</tr>
<tr>
<td>Visium</td>
<td>1</td>
</tr>
<tr>
<td>aging</td>
<td>1</td>
</tr>
</tbody>
</table>
<hr />
<h2>ğŸ“ æ›´å¤šå†…å®¹</h2>
<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (48æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301532" target="_blank" rel="noopener noreferrer">GSE301532 C9orf72çªå˜ä½“å’ŒåŒæºå¯¹ç…§äººiPSCè¡ç”Ÿå°èƒ¶è´¨ç»†èƒçš„å•ç»†èƒRNAæµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290095" target="_blank" rel="noopener noreferrer">GSE290095 2 å‹ç³–å°¿ç—…å† çŠ¶åŠ¨è„‰å¾®å¾ªç¯çš„ç©ºé—´è½¬å½•ç»„åˆ†ææ­ç¤ºäº†å¿ƒè„ä¸åŒåŒºåŸŸçš„å¼‚è´¨æ€§ [scRNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290094" target="_blank" rel="noopener noreferrer">GSE290094 2 å‹ç³–å°¿ç—…å† çŠ¶åŠ¨è„‰å¾®å¾ªç¯çš„ç©ºé—´è½¬å½•ç»„åˆ†ææ­ç¤ºäº†å¿ƒè„ä¸åŒåŒºåŸŸçš„å¼‚è´¨æ€§ [Visium]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285383" target="_blank" rel="noopener noreferrer">GSE285383 CCL5 é€šè¿‡è°ƒèŠ‚è¡€å°æ¿é©±åŠ¨çš„ M2 å·¨å™¬ç»†èƒæåŒ–ä¿ƒè¿›è¡€ç®¡ç´§å¼ ç´  II è¯±å¯¼çš„å¿ƒè„é‡å¡‘</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE283015" target="_blank" rel="noopener noreferrer">GSE283015 Spatial immune landscape of large artery atherosclerotic and cardioembolic thrombus retrieved from mechanical thrombectomy</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE276026" target="_blank" rel="noopener noreferrer">GSE276026 RNAæµ‹åºç ”ç©¶å‰åˆ—è…ºç™Œç»†èƒä¸­FZD6åŸºå› æ•²ä½çš„æƒ…å†µ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312476" target="_blank" rel="noopener noreferrer">GSE312476 TRC-051384 æ¿€æ´»çƒ­ä¼‘å…‹é€šè·¯ä¿æŠ¤èºæ—‹ç¥ç»èŠ‚ç¥ç»å…ƒå…å—å™ªå£°å¼•èµ·çš„å¬åŠ›æŸå¤± [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE174112" target="_blank" rel="noopener noreferrer">GSE174112 å•ç»†èƒè½¬å½•ç»„æ­ç¤ºäº†å“ºä¹³ä»”çŒªå’Œæ—©æœŸæ–­å¥¶ä»”çŒªå›è‚ çš„å¼‚è´¨æ€§å’Œä¸åŒçŠ¶æ€</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE165094" target="_blank" rel="noopener noreferrer">GSE165094 æ¡ƒæœå®å…¨åŸºå› ç»„äºšç¡«é…¸æ°¢ç›æµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116645" target="_blank" rel="noopener noreferrer">GSE116645 å…¨åŸºå› ç»„DNAç”²åŸºåŒ–ä»‹å¯¼å¯å˜å‰ªæ¥è½¬å½•æœ¬</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE109189" target="_blank" rel="noopener noreferrer">GSE109189 æ¢¨æœå®å…¨åŸºå› ç»„äºšç¡«é…¸æ°¢ç›æµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE109188" target="_blank" rel="noopener noreferrer">GSE109188 è‹¹æœæœå®å…¨åŸºå› ç»„äºšç¡«é…¸æ°¢ç›æµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313098" target="_blank" rel="noopener noreferrer">GSE313098 æ—¶é—´åºåˆ— RNA-seq åˆ†ææ­ç¤ºäº†æ…¢æ€§æ·‹å·´ç»†èƒç™½è¡€ç—… (CLL) è‡ªä½“å’Œå•åŸ¹å…»ä½“å¤–æ¨¡å‹ä¸­åŠ¨æ€çš„è½¬å½•ååº”å’Œç›¸äº’ä½œç”¨</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310345" target="_blank" rel="noopener noreferrer">GSE310345 è·¨ç‰©ç§å•ç»†èƒåˆ†ææ­ç¤ºçº¿ç²’ä½“åŠŸèƒ½éšœç¢çš„æ€§åˆ«å·®å¼‚æ˜¯ Tau ç—…ç†çš„ä¿å®ˆç‰¹å¾</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307293" target="_blank" rel="noopener noreferrer">GSE307293 å²©è—»ç³–åŸºè½¬ç§»é…¶ 8 è¡ç”Ÿçš„ç¯çŠ¶ RNA é€šè¿‡ ENO1-TNF ä¿¡å·é€šè·¯é©±åŠ¨å·¨å™¬ç»†èƒ M2 æåŒ–ï¼Œä»è€Œä¿ƒè¿›è‚ºç™Œè¿›å±•</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305935" target="_blank" rel="noopener noreferrer">GSE305935 æ¾³å¤§åˆ©äºšæµ·æ¹¾æˆ˜äº‰è€å…µçš„å…ç–«è½¬å½•ç»„å˜åŒ–</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305134" target="_blank" rel="noopener noreferrer">GSE305134 RORB åœ¨ç¥ç»æ¯ç»†èƒç˜¤ç»†èƒä¸­çš„å…¨åŸºå› ç»„å ä½æƒ…å†µã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302840" target="_blank" rel="noopener noreferrer">GSE302840 RPL22 è¡¨è¾¾é‰´å®šå‡º MLH1 ç¼ºé™·å‹å­å®«å†…è†œç™Œçš„ä¸€ä¸ªè½¬å½•äºšç¾¤ï¼Œè¯¥äºšç¾¤å½±å“è‚¿ç˜¤æµ¸æ¶¦æ·‹å·´ç»†èƒ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302839" target="_blank" rel="noopener noreferrer">GSE302839 RPL22 è¡¨è¾¾é‰´å®šå‡º MLH1 ç¼ºé™·å‹å­å®«å†…è†œç™Œçš„è½¬å½•äºšç¾¤ï¼Œè¯¥äºšç¾¤å½±å“è‚¿ç˜¤æµ¸æ¶¦æ·‹å·´ç»†èƒ [è›‹ç™½è´¨]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302749" target="_blank" rel="noopener noreferrer">GSE302749 RPL22 è¡¨è¾¾é‰´å®šå‡º MLH1 ç¼ºé™·å‹å­å®«å†…è†œç™Œçš„è½¬å½•äºšç¾¤ï¼Œè¯¥äºšç¾¤å½±å“è‚¿ç˜¤æµ¸æ¶¦æ·‹å·´ç»†èƒ [è½¬å½•æœ¬]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE299344" target="_blank" rel="noopener noreferrer">GSE299344 PARP å’Œ CLK/DYRK æŠ‘åˆ¶åœ¨è€è¯æ€§é«˜çº§åˆ«æµ†æ¶²æ€§ç™Œä¸­çš„ä½œç”¨</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297829" target="_blank" rel="noopener noreferrer">GSE297829 å•ç»†èƒ RNA æµ‹åºæ­ç¤ºäº†æ¥å—é€æ 3 å¹´æ‚£è€…è…¹è†œå¾®ç¯å¢ƒçš„åŠ¨æ€å˜åŒ–ï¼Œå¹¶ä¸ºè…¹è†œçº¤ç»´åŒ–æä¾›äº†æ–°çš„è§è§£ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296196" target="_blank" rel="noopener noreferrer">GSE296196 SIRPGä»¥CD47éä¾èµ–æ€§æ–¹å¼å¢å¼ºæ´»åŒ–è¯±å¯¼çš„Tç»†èƒå¢æ®–</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293768" target="_blank" rel="noopener noreferrer">GSE293768 VTC3 å’Œ VTC2 å¯¹æ‹Ÿå—èŠ¥å…‰ç…§ä¸‹è½¬å½•ç»„çš„å½±å“</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287861" target="_blank" rel="noopener noreferrer">GSE287861 ç ”ç©¶å‘ç°ï¼Œå…³èŠ‚è½¯éª¨ä¸­ GATA4 æ°´å¹³çš„è¡°è€ç›¸å…³æ€§å‡é«˜ä¸è½¯éª¨ç»†èƒå†ç”Ÿèƒ½åŠ›å—æŸå’Œéª¨å…³èŠ‚ç‚æœ‰å…³ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE278347" target="_blank" rel="noopener noreferrer">GSE278347 CEBPB drives endothelial pathological phenotype and promotes atherosclerosis by directly upregulating TGFBR1 expression [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE278346" target="_blank" rel="noopener noreferrer">GSE278346 CEBPB é€šè¿‡ç›´æ¥ä¸Šè°ƒ TGFBR1 è¡¨è¾¾é©±åŠ¨å†…çš®ç—…ç†è¡¨å‹å¹¶ä¿ƒè¿›åŠ¨è„‰ç²¥æ ·ç¡¬åŒ– [scRNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313261" target="_blank" rel="noopener noreferrer">GSE313261 å°é¼ è„¾è„ä¸­IL-33ã€IL-25ã€IL-13ã€TSLPã€IL-4å’ŒIL-9è¿‡è¡¨è¾¾çš„å…¨å±€è½¬å½•ç»„åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313259" target="_blank" rel="noopener noreferrer">GSE313259 Apoe3 é€šè¿‡ Lrp4 å¢å¼ºä¹™é…°èƒ†ç¢±å—ä½“èšé›†</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313176" target="_blank" rel="noopener noreferrer">GSE313176 MÃ¼llerç»†èƒè°·æ°¨é…°èƒºä»£è°¢å°†ç³–å°¿ç—…è§†ç½‘è†œç—…å˜ä¸­çš„å…‰æ„Ÿå—å™¨å’Œå†…çš®æŸä¼¤è”ç³»èµ·æ¥</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313146" target="_blank" rel="noopener noreferrer">GSE313146 ä¸Šçš® miRNA çš„ä¸Šè°ƒä¸è¿›è¡Œæ€§æ”¯æ°”ç®¡ç™Œå‰ç—…å˜ä¸­çš„å…ç–«é€ƒé€¸æœ‰å…³ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313145" target="_blank" rel="noopener noreferrer">GSE313145 ä¸Šçš® miRNA çš„ä¸Šè°ƒä¸è¿›è¡Œæ€§æ”¯æ°”ç®¡ç™Œå‰ç—…å˜ä¸­çš„å…ç–«é€ƒé€¸ç›¸å…³ [PCGA_miRNA_BX]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313144" target="_blank" rel="noopener noreferrer">GSE313144 ä¸Šçš® miRNA çš„ä¸Šè°ƒä¸è¿›è¡Œæ€§æ”¯æ°”ç®¡ç™Œå‰ç—…å˜ä¸­çš„å…ç–«é€ƒé€¸ç›¸å…³ [PCGA_miRNA_BR]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313043" target="_blank" rel="noopener noreferrer">GSE313043 å•ç»†èƒè½¬å½•ç»„åˆ†æè¡¨æ˜ï¼Œè„‘å‡ºè¡€æœŸé—´æ¥å— BAF312 æ²»ç–—çš„æ‚£è€… TNF ä¿¡å·ä¼ å¯¼é™ä½</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291568" target="_blank" rel="noopener noreferrer">GSE291568 å«SETç»“æ„åŸŸçš„è›‹ç™½è´¨å’ŒHCF-1ç»´æŒè·¨ä»£è¡¨è§‚é—ä¼ è®°å¿†</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291081" target="_blank" rel="noopener noreferrer">GSE291081 Ly6G+Nur77+è¡€ç®¡å‘¨å›´å·¨å™¬ç»†èƒå¯åŠ¨è‚ºéƒ¨å¯¹è¿‡æ•åŸçš„2å‹å…ç–«ååº”</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289548" target="_blank" rel="noopener noreferrer">GSE289548 Ly6G+Nur77+å·¨å™¬ç»†èƒå¯åŠ¨è‚ºéƒ¨å¯¹è¿‡æ•åŸçš„2å‹å…ç–«ååº”</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311370" target="_blank" rel="noopener noreferrer">GSE311370 å°é¼ è§†ç½‘è†œç¥ç»èŠ‚ç»†èƒçš„å®Œæ•´ç©ºé—´å›¾è°±æ­ç¤ºäº†å¯†åº¦å’ŒåŸºå› è¡¨è¾¾ç‰¹åŒ– [En face Retina]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311369" target="_blank" rel="noopener noreferrer">GSE311369 å°é¼ è§†ç½‘è†œç¥ç»èŠ‚ç»†èƒçš„å®Œæ•´ç©ºé—´å›¾è°±æ­ç¤ºäº†å¯†åº¦å’ŒåŸºå› è¡¨è¾¾ç‰¹åŒ– [RGC_CrossSection]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305119" target="_blank" rel="noopener noreferrer">GSE305119 Ly6G+Nur77+å·¨å™¬ç»†èƒå¯åŠ¨è‚ºéƒ¨å¯¹è¿‡æ•åŸçš„2å‹å…ç–«ååº”</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281797" target="_blank" rel="noopener noreferrer">GSE281797 è‚¥èƒ–ä»£è°¢åŠŸèƒ½éšœç¢ç›¸å…³è„‚è‚ªè‚æ‚£è€…è‚è„æ´»æ£€çš„è½¬å½•ç»„å­¦ç‰¹å¾</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310742" target="_blank" rel="noopener noreferrer">GSE310742 FABP4 æ˜¯å¿ƒè¡€ç®¡ç–¾ç—…é¢„åä¸è‰¯çš„æ ‡å¿—ç‰©ï¼Œå®ƒèƒ½è¯±å¯¼ä¸­æ€§ç²’ç»†èƒäº§ç”Ÿä¿ƒåŠ¨è„‰ç²¥æ ·ç¡¬åŒ–çš„è¡¨å‹ï¼Œè€Œè¿™ç§è¡¨å‹å¯è¢«ç´¢ç›é²è‚½è°ƒèŠ‚ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291990" target="_blank" rel="noopener noreferrer">GSE291990 Z-DNA å½¢æˆè¯±å¯¼å…¨èƒ½æ€§æ ·çŠ¶æ€å¹¶å¯åŠ¨ Zscan4 ä¾èµ–æ€§æŸ“è‰²è´¨åŒºå®¤åŒ– [scRNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291987" target="_blank" rel="noopener noreferrer">GSE291987 Z-DNA å½¢æˆè¯±å¯¼å…¨èƒ½æ ·çŠ¶æ€å¹¶å¯åŠ¨ Zscan4 ä¾èµ–çš„æŸ“è‰²è´¨åŒºå®¤åŒ– [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291983" target="_blank" rel="noopener noreferrer">GSE291983 Z-DNA å½¢æˆè¯±å¯¼å…¨èƒ½æ ·çŠ¶æ€å¹¶å¯åŠ¨ Zscan4 ä¾èµ–çš„æŸ“è‰²è´¨åŒºå®¤åŒ– [Hi-C]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE284076" target="_blank" rel="noopener noreferrer">GSE284076 tRNA ç‰‡æ®µçš„è½¬å½•åä¿®é¥°èµ‹äºˆåŠ¨è„‰ç²¥æ ·ç¡¬åŒ–ä¸­é«˜å¯†åº¦è„‚è›‹ç™½åŠŸèƒ½æ”¹å˜ [å° RNA æµ‹åº]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE284071" target="_blank" rel="noopener noreferrer">GSE284071 tRNA ç‰‡æ®µçš„è½¬å½•åä¿®é¥°èµ‹äºˆåŠ¨è„‰ç²¥æ ·ç¡¬åŒ–ä¸­é«˜å¯†åº¦è„‚è›‹ç™½åŠŸèƒ½æ”¹å˜ [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE270833" target="_blank" rel="noopener noreferrer">GSE270833 æ ¸ç›¸åˆ†ç¦»é©±åŠ¨æ€¥æ€§é«“ç³»ç™½è¡€ç—…</a></li>
</ul>
</div>
</details>

<hr />
<p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2025-12-11 21:39</em><br />
<em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p>
    </div>
</body>
</html>